EyePoint Pharmaceuticals (EYPT)
(Delayed Data from NSDQ)
$9.10 USD
-0.17 (-1.83%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $9.08 -0.02 (-0.22%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
EYEPOINT PHARMACEUTICALS, INC. [EYPT]
Reports for Purchase
Showing records 41 - 60 ( 82 total )
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
ILUVIEN Royalty Monetized; Reverse Stock Split; Adjusting PT to $16
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
EYP-1901 Positive GLP Toxicology Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Debt Covenant Amended; Upgrading to Buy With $2 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Preliminary 3Q20 Product Revenue Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Additional Licensing Payment Received; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
2Q20 Financial Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Commercial Reorganization and Work Force Reduction Due to COVID-19; Reiterate Neutra
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
4Q and Full-Year 2019 Financial Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Positive 36-Month Data from Second YUTIQ Phase 3 Trial; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Purchase Agreement for DEXYCU Inked; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Tyrosine Kinase Inhibitor In-licensed for Wet AMD; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
DEXYCU Greater China Rights Out-Licensed; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
4Q19 and Full-Year 2019 Preliminary Financial Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
3Q19 Results Reported; Near-Term Financial Foe; Downgrading to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
New DEXYCU and YUTIQ Commercial Agreements Inked; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Cataract Surgery Day Showcases DEXYCU; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
J-code Assigned for YUTIQ Reimbursement; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Finance Chief Departure Unlikely to Cause Negative Impact, in Our View; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y